Gaido Health

Gaido Health developed an AI-driven digital therapeutics solution for remotely monitoring oncology patients at home. The system combined wearable biosensors, patient-reported outcomes via surveys, and advanced analytics to detect early signs of complications following cancer therapies such as chemotherapy or CAR-T cell therapy. This approach aimed to reduce hospital readmissions and emergency visits by enabling earlier clinical intervention. The company was acquired by Biofourmis in April 2020; its technology has since been integrated into the FDA-cleared Biovitals platform for broader commercial deployment in oncology care pathways.